Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL27598945 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8378216 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL40902 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27706849 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29846325 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL14109970 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL147362 | 0.99 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119855595-A | IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification | 萨尼菲特治疗有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118523308-A | Short-term power load prediction method and device based on deep learning and storage medium | 无锡英臻科技股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| WO-2024047037-A1 | COMPOSITIONS FOR PARENTERAL SUSTAINED RELEASE DELIVERY OF HYDROPHILIC DRUGS | ETH Zürich (CH) | 2024-03-07 | — | — | WO | claimed |
| CN-113788855-B | Inositol derivatives for pathological crystallization | 苏黎世联邦理工学院 | 2024-03-01 | — | — | CN | claimed |
| CN-116745304-A | IP4-4,6 substituted derivative compounds | 萨尼菲特治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115427418-A | Inositol derivative and application thereof | 上海森辉医药有限公司 | 2022-12-02 | — | — | CN | claimed |
| CN-122080055-A | Inositol phosphate compounds for treating, inhibiting progression of or preventing cardiovascular calcification | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4724048-A1 | ORAL SOLID PHARMACEUTICAL FORMULATION COMPRISING METHADONE/LEVOMETHADONE AND OPTIONALLY NALOXONE | L. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETA' DI ESERCIZIO S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| EP-3587896-B1 | GAS SUPPLY REGULATOR | CLESSE IND (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250232198-A1 | SYSTEM AND METHOD FOR AUTOCORRECTING QUANTUM RANDOM NUMBERS GENERATION | HCL TECHNOLOGIES LIMITED (IN) | 2025-07-17 | — | — | US | disclosed |
| CN-120131675-A | Inositol phosphates for treatment of ectopic calcification | 萨尼菲特治疗有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025091797-A1 | SERVER HARDWARE EXCEPTION EARLY WARNING METHOD AND APPARATUS, DEVICE AND STORAGE MEDIUM | 苏州元脑智能科技有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119855595-A | IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification | 萨尼菲特治疗有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | SALIX PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115955679-A | Distributed particle swarm optimization algorithm based on mobile base station | 常州工学院 | 2023-04-11 | — | — | CN | disclosed |
| EP-4121746-A1 | IN-FIELD COLOUR TEST FOR SCREENING FENTANYL AND ANALOGUES THEREOF | University Of Technology Sydney (AU) | 2023-01-25 | — | — | EP | disclosed |
| CN-115427418-A | Inositol derivative and application thereof | 上海森辉医药有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114883250-A | Interconnect structure | 台湾积体电路制造股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220096460-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2022-03-31 | — | — | US | disclosed |
| CN-114237254-A | Unmanned ship rudder direction PID control design method based on Smith predictor and particle swarm algorithm | 中国海洋大学 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | MTNR1A, OPRL1, OPRK1 | OPRM1 6/4885OPRD1 13/4885OPRK1 3/4885 |
| US-20220096460-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 4/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.